Patents by Inventor Guangmei Yan
Guangmei Yan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11911396Abstract: Disclosed is use of 5?-androst-3?,5,6?-triol or an analogue, a deuterated compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cerebral small vessel disease in a patient. The cerebral small vessel disease is preferably cerebral microbleed. The cerebral microbleed is spontaneous cerebral microbleed, drug-related cerebral microbleed, or traumatic cerebral microbleed. The present invention demonstrates that these compounds significantly enhance the clearance of extravascular hemoglobin, and thus can be used to treat cerebral small vessel disease.Type: GrantFiled: December 28, 2018Date of Patent: February 27, 2024Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTDInventors: Guangmei Yan, Wei Yin, Longxiang Sheng, Bingzheng Lu, Yijun Huang, Suizhen Lin
-
Publication number: 20230167195Abstract: Provided are applications of a hexokinase 2-specific inhibitor in preparing a medicament for preventing and treating acute central nervous system injury.Type: ApplicationFiled: January 11, 2023Publication date: June 1, 2023Applicant: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTDInventors: Guangmei YAN, Wei YIN, Yuan LI, Bingzheng LU, Longxiang SHENG
-
Patent number: 11584802Abstract: Provided are applications of a hexokinase 2-specific inhibitor in preparing a medicament for preventing and treating acute central nervous system injury.Type: GrantFiled: February 6, 2018Date of Patent: February 21, 2023Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.Inventors: Guangmei Yan, Wei Yin, Yuan Li, Bingzheng Lu, Longxiang Sheng
-
Publication number: 20220315903Abstract: Provided is an M1 virus. Further provided are a series of uses of said virus. The uses include, but are not limited to, viral vectors, anti-tumor agents, and pharmaceutical compositions. Said virus can effectively inhibit the growth of various tumor cells, and at the same time, has tumor targeting properties and is non-toxic to normal cells. Said virus can be administrated by means of intravenous injection, having operational convenience.Type: ApplicationFiled: May 31, 2020Publication date: October 6, 2022Inventors: Guangmei YAN, Yuan LIN, Li GUO, Ziqing LIN, Guang'en WU
-
Patent number: 11382921Abstract: Disclosed is a use of 5?-androstane-3?,5,6?-triol, an analogue, a deuterated derivative, and a pharmaceutically acceptable salt thereof in manufacture of a medicament for the treatment of hemorrhagic stroke in a patient. The hemorrhagic stroke is intracerebral hemorrhage or subarachnoid hemorrhage.Type: GrantFiled: December 28, 2018Date of Patent: July 12, 2022Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTDInventors: Guangmei Yan, Yijun Huang, Wei Yin, Suizhen Lin
-
Patent number: 11234968Abstract: The present invention belongs to the field of biomedicine and relates to use of VCP (valosin-containing protein, VCP) inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that VCP inhibitor can be used in the preparation of an anti-tumor synergist for oncolytic virus. Meanwhile, the present invention relates to a pharmaceutical composition comprising VCP inhibitor and oncolytic virus, a pharmaceutical kit comprising VCP inhibitor and oncolytic virus, and use of VCP inhibitor and oncolytic virus for treating tumor, especially a tumor that is not sensitive to oncolytic virus. The present invention also relates to an anti-tumor administration system, characterized in that, comprising oncolytic virus and a reagent for detecting the expression level of VCP.Type: GrantFiled: August 18, 2017Date of Patent: February 1, 2022Assignee: Guangzhou Virotech Pharmaceutical Co., Ltd.Inventors: Guangmei Yan, Haipeng Zhang, Yuan Lin, Suizhen Lin, Jing Cai, Shoufang Gong, Jun Hu, Xiao Xiao, Kai Li, Jiankai Liang, Yaqian Tan, Wenbo Zhu, Wei Yin
-
Patent number: 11235011Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.Type: GrantFiled: November 12, 2019Date of Patent: February 1, 2022Assignee: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD.Inventors: Guangmei Yan, Xiao Xiao, Jun Hu, Kai Li, Jiankai Liang, Yuan Lin, Haipeng Zhang, Suizhen Lin
-
Publication number: 20210228660Abstract: Use of a proteasome inhibitor and an alphavirus in the preparation of an anti-tumor medicament. The proteasome inhibitor can be used to prepare an alphavirus anti-tumor synergist. A pharmaceutical composition comprising a proteasome inhibitor and an alphavirus, including a pharmaceutical kit comprising the proteasome inhibitor and the alphavirus, and use of the proteasome inhibitor and the virus in the treatment of tumors, particularly tumors insensitive to the alphavirus.Type: ApplicationFiled: May 22, 2019Publication date: July 29, 2021Inventors: Guangmei YAN, Haipeng ZHANG, Wenbo ZHU, Yuan LIN, Shoufang GONG, Jiankai LIANG, Jing CAI, Chunqiang LIU
-
Patent number: 10980850Abstract: Described herein is use of a Caspase activator and an oncolytic virus in the preparation of an anti-tumor drug. As described, Caspase activator can enhance the anti-tumor effect of oncolytic virus, and the combination of Caspase activator and oncolytic virus produces a significant synergistic anti-tumor effect, and demonstrates an effective therapy for the treatment of tumors that are less sensitive to other pharmaceutical treatments.Type: GrantFiled: August 18, 2017Date of Patent: April 20, 2021Assignee: Guangzhou Virotech Phamaceutical Co., Ltd.Inventors: Guangmei Yan, Jing Cai, Yuan Lin, Haipeng Zhang, Suizhen Lin, Shoufang Gong, Jun Hu, Xiao Xiao, Kai Li, Jiankai Liang, Yaqian Tan, Wenbo Zhu, Wei Yin
-
Publication number: 20210060035Abstract: Disclosed is a use of 5?-androstane-3?,5,6?-triol, an analogue, a deuterated derivative, and a pharmaceutically acceptable salt thereof in manufacture of a medicament for the treatment of hemorrhagic stroke in a patient. The hemorrhagic stroke is intracerebral hemorrhage or subarachnoid hemorrhage.Type: ApplicationFiled: December 28, 2018Publication date: March 4, 2021Applicant: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTDInventors: Guangmei YAN, Yijun HUANG, Wei YIN, Suizhen LIN
-
Publication number: 20200405793Abstract: Disclosed is the use of a mevalonate metabolic pathway inhibitor and an alphavirus in preparing an anti-tumor drug. The mevalonate metabolic pathway inhibitor can be used in preparing an alphavirus anti-tumor synergist. Disclosed are a pharmaceutical composition containing the mevalonate metabolic pathway inhibitor and the alphavirus, a drug kit containing the mevalonate metabolic pathway inhibitor and the alphavirus, and the use of the mevalonate metabolic pathway inhibitor and the alphavirus in treating tumors, especially those that are insensitive to the alphavirus.Type: ApplicationFiled: December 28, 2018Publication date: December 31, 2020Inventors: Guangmei YAN, Jiankai LIANG, Wenbo ZHU, Haipeng ZHANG, Yuan LIN, Jing CAI, Shoufang GONG
-
Publication number: 20200392250Abstract: Provided are applications of a hexokinase 2-specific inhibitor in preparing a medicament for preventing and treating acute central nervous system injury.Type: ApplicationFiled: February 6, 2018Publication date: December 17, 2020Applicant: Guangzhou Cellprotek Pharmaceutical Co., Ltd.Inventors: Guangmei YAN, Wei YIN, Yuan LI, Bingzheng LU, Longxiang SHENG
-
Patent number: 10835539Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.Type: GrantFiled: March 25, 2019Date of Patent: November 17, 2020Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
-
Publication number: 20200330483Abstract: Disclosed is use of 5?-androst-3?,5,6?-triol or an analogue, a deuterated compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cerebral small vessel disease in a patient. The cerebral small vessel disease is preferably cerebral microbleed. The cerebral microbleed is spontaneous cerebral microbleed, drug-related cerebral microbleed, or traumatic cerebral microbleed. The present invention demonstrates that these compounds significantly enhance the clearance of extravascular hemoglobin, and thus can be used to treat cerebral small vessel disease.Type: ApplicationFiled: December 28, 2018Publication date: October 22, 2020Applicant: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTDInventors: Guangmei YAN, Wei YIN, Longxiang SHENG, Bingzheng LU, Yijun HUANG, Suizhen LIN
-
Publication number: 20200085892Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.Type: ApplicationFiled: November 12, 2019Publication date: March 19, 2020Applicant: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTDInventors: Guangmei YAN, Xiao XIAO, Jun HU, Kai LI, Jiankai LIANG, Yuan LIN, Haipeng ZHANG, Suizhen LIN
-
Patent number: 10517909Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.Type: GrantFiled: August 24, 2015Date of Patent: December 31, 2019Assignee: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTDInventors: Guangmei Yan, Xiao Xiao, Jun Hu, Kai Li, Jiankai Liang, Yuan Lin, Haipeng Zhang, Suizhen Lin
-
Publication number: 20190262358Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.Type: ApplicationFiled: March 25, 2019Publication date: August 29, 2019Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
-
Patent number: 10357500Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.Type: GrantFiled: April 14, 2015Date of Patent: July 23, 2019Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
-
Publication number: 20190183948Abstract: This invention belongs to the field of biomedicine and relates to use of Bcl-xL inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that the Bcl-xL inhibitor can be used as an anti-tumor synergist for oncolytic virus. The present invention also relates to a pharmaceutical composition comprising Bcl-xL inhibitor and oncolytic virus, a pharmaceutical kit comprising Bcl-xL inhibitor and oncolytic virus, and use of Bcl-xL inhibitor and oncolytic virus for treating tumors, especially, tumors that are not sensitive to the oncolytic virus.Type: ApplicationFiled: August 18, 2017Publication date: June 20, 2019Applicant: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD.Inventors: Guangmei YAN, Yaqian TAN, Yuan LIN, Haipeng ZHANG, Suizhen LIN, Shoufang GONG, Jun HU, Xiao XIAO, Kai LI, Jiankai LIANG, Jing CAI, Wenbo ZHU, Wei YIN
-
Publication number: 20190167641Abstract: The present invention belongs to the field of biomedicine and relates to use of VCP (valosin-containing protein, VCP) inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that VCP inhibitor can be used in the preparation of an anti-tumor synergist for oncolytic virus. Meanwhile, the present invention relates to a pharmaceutical composition comprising VCP inhibitor and oncolytic virus, a pharmaceutical kit comprising VCP inhibitor and oncolytic virus, and use of VCP inhibitor and oncolytic virus for treating tumor, especially a tumor that is not sensitive to oncolytic virus. The present invention also relates to an anti-tumor administration system, characterized in that, comprising oncolytic virus and a reagent for detecting the expression level of VCP.Type: ApplicationFiled: August 18, 2017Publication date: June 6, 2019Applicant: Guangzhou Virotech Pharmaceutical Co., Ltd.Inventors: Guangmei YAN, Haipeng ZHANG, Yuan LIN, Suizhen LIN, Jing CAI, Shoufang GONG, Jun HU, Xiao XIAO, Kai LI, Jiankai LIANG, Yaqian TAN, Wenbo ZHU, Wei YIN